Shandong Sinobioway Biomedicine's high P/S ratio indicates a potential risk of share price decrease. Investors might pay excessive premium if recent medium-term revenue trends persist. The expected business turnaround could lead to disappointment if the P/S ratio aligns more with recent growth rates.
未名医药股票讨论区
暂无评论